vs
Enact Holdings, Inc.（ACT）与Esperion Therapeutics, Inc.（ESPR）财务数据对比。点击上方公司名可切换其他公司
Enact Holdings, Inc.的季度营收约是Esperion Therapeutics, Inc.的1.9倍（$312.7M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 3.6%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 3.6%）
Enact Holdings, Inc.是美国领先的私人抵押贷款保险服务商，为银行、信用社等各类住宅抵押贷款机构提供风险缓释解决方案，帮助首付较低的购房者获得可负担的住房贷款，助力更多美国普通消费者实现安居需求。
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
ACT vs ESPR — 直观对比
营收规模更大
ACT
是对方的1.9倍
$168.4M
营收增速更快
ESPR
高出140.1%
3.6%
两年增速更快
ESPR
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $312.7M | $168.4M |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | 71.3% | 50.6% |
| 净利率 | — | — |
| 营收同比 | 3.6% | 143.7% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $1.23 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTESPR
| Q4 25 | $312.7M | $168.4M | ||
| Q3 25 | $311.5M | $87.3M | ||
| Q2 25 | $304.9M | $82.4M | ||
| Q1 25 | $306.8M | $65.0M | ||
| Q4 24 | $301.8M | $69.1M | ||
| Q3 24 | $309.6M | $51.6M | ||
| Q2 24 | $298.8M | $73.8M | ||
| Q1 24 | $291.6M | $137.7M |
净利润ACTESPR
| Q4 25 | — | — | ||
| Q3 25 | — | $-31.3M | ||
| Q2 25 | — | $-12.7M | ||
| Q1 25 | — | $-40.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-29.5M | ||
| Q2 24 | — | $-61.9M | ||
| Q1 24 | — | $61.0M |
营业利润率ACTESPR
| Q4 25 | 71.3% | 50.6% | ||
| Q3 25 | 67.4% | -11.4% | ||
| Q2 25 | 70.4% | 8.6% | ||
| Q1 25 | 68.9% | -34.0% | ||
| Q4 24 | 68.9% | -6.4% | ||
| Q3 24 | 74.1% | -31.0% | ||
| Q2 24 | 78.6% | 3.5% | ||
| Q1 24 | 70.6% | 52.5% |
净利率ACTESPR
| Q4 25 | — | — | ||
| Q3 25 | — | -35.9% | ||
| Q2 25 | — | -15.4% | ||
| Q1 25 | — | -62.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -57.2% | ||
| Q2 24 | — | -83.9% | ||
| Q1 24 | — | 44.3% |
每股收益（稀释后）ACTESPR
| Q4 25 | $1.23 | $0.32 | ||
| Q3 25 | $1.10 | $-0.16 | ||
| Q2 25 | $1.11 | $-0.06 | ||
| Q1 25 | $1.08 | $-0.21 | ||
| Q4 24 | $1.05 | $-0.14 | ||
| Q3 24 | $1.15 | $-0.15 | ||
| Q2 24 | $1.16 | $-0.33 | ||
| Q1 24 | $1.01 | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $582.5M | $167.9M |
| 总债务越低越好 | $744.5M | — |
| 股东权益账面价值 | $5.4B | $-302.0M |
| 总资产 | $6.9B | $465.9M |
| 负债/权益比越低杠杆越低 | 0.14× | — |
8季度趋势，按日历期对齐
现金及短期投资ACTESPR
| Q4 25 | $582.5M | $167.9M | ||
| Q3 25 | $545.6M | $92.4M | ||
| Q2 25 | $616.0M | $86.1M | ||
| Q1 25 | $639.0M | $114.6M | ||
| Q4 24 | $602.8M | $144.8M | ||
| Q3 24 | $674.9M | $144.7M | ||
| Q2 24 | $711.3M | $189.3M | ||
| Q1 24 | $624.3M | $226.6M |
总债务ACTESPR
| Q4 25 | $744.5M | — | ||
| Q3 25 | $744.1M | — | ||
| Q2 25 | $743.8M | — | ||
| Q1 25 | $743.4M | — | ||
| Q4 24 | $743.0M | — | ||
| Q3 24 | $742.7M | — | ||
| Q2 24 | $742.4M | — | ||
| Q1 24 | $746.1M | — |
股东权益ACTESPR
| Q4 25 | $5.4B | $-302.0M | ||
| Q3 25 | $5.3B | $-451.4M | ||
| Q2 25 | $5.2B | $-433.5M | ||
| Q1 25 | $5.1B | $-426.2M | ||
| Q4 24 | $5.0B | $-388.7M | ||
| Q3 24 | $5.0B | $-370.2M | ||
| Q2 24 | $4.8B | $-344.2M | ||
| Q1 24 | $4.7B | $-294.3M |
总资产ACTESPR
| Q4 25 | $6.9B | $465.9M | ||
| Q3 25 | $6.9B | $364.0M | ||
| Q2 25 | $6.8B | $347.1M | ||
| Q1 25 | $6.7B | $324.0M | ||
| Q4 24 | $6.5B | $343.8M | ||
| Q3 24 | $6.6B | $314.1M | ||
| Q2 24 | $6.3B | $352.3M | ||
| Q1 24 | $6.3B | $373.1M |
负债/权益比ACTESPR
| Q4 25 | 0.14× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $724.5M | $45.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ACTESPR
| Q4 25 | $724.5M | $45.2M | ||
| Q3 25 | $192.0M | $-4.3M | ||
| Q2 25 | $119.5M | $-31.4M | ||
| Q1 25 | $226.7M | $-22.6M | ||
| Q4 24 | $686.3M | $-35.0M | ||
| Q3 24 | $188.1M | $-35.3M | ||
| Q2 24 | $144.7M | $-7.2M | ||
| Q1 24 | $187.3M | $53.8M |
自由现金流ACTESPR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $53.8M |
自由现金流率ACTESPR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% | ||
| Q1 24 | — | 39.0% |
资本支出强度ACTESPR
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
现金转化率ACTESPR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACT
暂无分部数据
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
